Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

9475	Companies
185442	Keywords
117783	Articles
99298	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 07/15/2025 at 07:00, 4 months 21 days ago

Biophytis Partners in AI with Lynx Analytics to Accelerate Drug Discovery for Sarcopenia
Biophytis partners with Lynx Analytics to accelerate drug discovery for sarcopenia through AI collaboration. The partnership aims to develop small molecule drugs for muscle preservation and regeneration

Biophytis Drug Discovery AI Sarcopenia Lynx Analytics
BRIEF

published on 07/11/2025 at 08:19, 4 months 25 days ago

Biophytis Reports 2024 Financial Results and Strategy for 2025

Drug Discovery Partnerships Biophytis Financials 2025 Strategic Plans Phase 2 And Phase 3 Trials
REGULATED PRESS RELEASE

published on 07/11/2025 at 08:14, 4 months 25 days ago

Biophytis Reports 2024 Financial Results and 2025 Outlook
Biophytis announces 2024 financial results, 2025 outlook. Initiates Phase 2 study in obesity, Phase 3 study in sarcopenia. Strengthens drug discovery platform. Resumes trading on Euronext Growth Paris

Financial Results Biophytis Drug Discovery Phase 3 Phase 2
BRIEF

published on 07/08/2025 at 07:05, 4 months 28 days ago

Biophytis Highlights Longevity Innovation at ARC 2025

Innovation Biophytis Longevity Sarcopenia ARC 2025
REGULATED PRESS RELEASE

published on 07/08/2025 at 07:00, 4 months 28 days ago

Biophytis at the Forefront of Longevity Innovation at the World Aging & Rejuvenation Conference 2025
Biophytis SA announces participation in ARC 2025 to present results of BIO101 in sarcopenia at the World Aging & Rejuvenation Conference, aiming to strengthen scientific visibility and expand in the longevity market

Sarcopenia Biophytis SA BIO101 Longevity Market ARC 2025
BRIEF

published on 07/07/2025 at 07:05, 4 months 29 days ago

Biophytis Aims to Address Muscle Loss in Obesity Market

Biophytis BIO101 Muscle Preservation GLP-1 Therapies Obesity Market
REGULATED PRESS RELEASE

published on 07/07/2025 at 07:00, 4 months 29 days ago

Obesity: Biophytis Charts Its Course Toward a Booming Market
Biophy.s SA is focusing on developing transformative therapies for obesity, sarcopenia, and longevity by addressing muscle loss with its lead drug BIO101. The company's strategic positioning targets the expanding obesity market

BIO101 Obesity Market Opportunity Muscle Loss Biophy.s SA
BRIEF

published on 07/03/2025 at 07:05, 5 months 2 days ago

Biophytis Showcases Innovations at BIO International 2025

Biophytis Precision Medicine Longevity Sarcopenia Obesity Therapy
REGULATED PRESS RELEASE

published on 07/03/2025 at 07:00, 5 months 2 days ago

Biophythis Powers Innovation in Obesity, Muscle Health, and Longevity at BIO International 2025
Biophytis highlights innovations in obesity, muscle health, and longevity at BIO International 2025, showcasing therapies targeting key health challenges. Strategic partnerships post-conference aim to accelerate therapies' global impact

Innovations Longevity Obesity Muscle Health Biophy(s
BRIEF

published on 06/30/2025 at 22:35, 5 months 4 days ago

Biophytis Delays Publication of 2024 Annual Financial Statements

Biophytis Biotechnology Drug Development Annual Accounts Financial Delay

Accesswire

Published on 12/05/2025 at 02:35, 9 hours 7 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 9 hours 12 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 10 hours 42 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 12 hours 37 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 12 hours 42 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 11:14, 28 minutes ago

Halfords Group PLC: Director/PDMR Shareholding
Published on 12/05/2025 at 10:30, 1 hour 12 minutes ago

Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 1 hour 27 minutes ago

Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 2 hours 2 minutes ago

Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 2 hours 12 minutes ago

REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany

Les Echos

Published on 12/05/2025 at 08:45, 2 hours 57 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 17 hours 42 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 17 hours 57 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 17 hours 58 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 4 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE